wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

Question Set 3

Total questions: 10

Worksheet time: 3mins

Name
Class
Date
1.

Lung cancer is 2 nd common cancer in Vietnam. Please advise what is the number of new

patients acquired lung cancer per year in Vietnam according to GlobalCAN 2018?

a)

23, 667

b)

24, 667

c)

25,667

2.

ALK is one of rare mutation in lung cancer. The percentage of ALK mutation in lung

cancer patients is?

a)

1% - 3%

b)

3% - 5%

c)

5% - 7%

3.

Alecensa (Alectinib) increases our belief about curable therapy in lung cancer. Please

share how long of PFS this brand offered to lung cancer, ALK (+)?

a)

PFS > 33.8 months

b)

PFS > 34.8 months

c)

PFS > 36.8 months

4.

Tecentriq (Atezolizumab) recovers natural body immune system to kill cancer cells

through PL-L1 pathway. Please recall what was the key benefit of Tecentriq in 2 nd line

treatment of lung cancer?

a)

OS # 13.8 months

b)

OS # 14.8 months

c)

OS # 15.8 months

5.

In the near future, Roche Vietnam would offer more effective therapies in lung cancer

patients including of:

a)

2L Tecentriq, Alecensa, A + T and T plus A

b)

1L Tecentriq, Alecensa, A + T (Avastin + Tarceva), T + A (Tecentriq + Avastin)

c)

Alecensa, A + T and T plus A

6.

How long of PFS ‘A + T’ (Avastin plus Tarceva) offered in lung cancer, EGFR (+)?

a)

PFS 15.9 months

b)

PFS 16.9 months

c)

PFS 17.9 month

7.

Colorectal cancer (CRC) is 5 th common cancer in Vietnam. Please advise what is the

number of new patients acquired CRC per year in Vietnam according to GlobalCAN

2018?

a)

14,733

b)

15,733

c)

16,733

8.

Avastin (Bevacizumab) is an anti-angiogenesis therapy which was approved for mCRC

treatment since 2004. Please recall what was the key benefit of this brand in mCRC?

a)

OS > 20 months regardless RAS, Chemo & Age

b)

PFS > 20 months regardless RAS, Chemo & Age

c)

DFS > 20 months regardless RAS, Chemo & Age

9.

How you know about liver cancer in Vietnam according to GlobalCAN 2018?

a)

1st common cancer

b)

3rd common cancer

c)

4th common cancer

10.

In future, which brand can extend our leadership in Hepatocellular carcinoma (HCC)?

a)

Avastin

b)

Tecentriq

c)

The combination of Tecentriq plus Avastin